XmAb24306
- Generic Name
- XmAb24306
- Drug Type
- Biotech
- Background
XmAb24306 is an investigational cancer immunotherapy. It is a heterodimeric interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) complex fused to a bispecific Fc domain.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05646836
- Locations
- ๐ฆ๐บ
Peter Maccallum Cancer Centre, Melbourne, Victoria, Australia
๐ฆ๐บAlfred Hospital, Melbourne, Victoria, Australia
๐ฉ๐ฐSygehus Lillebaelt - Vejle Sygehus, Vejle, Denmark
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05243342
- Locations
- ๐ณ๐ด
Oslo Universitetssykehus HF, Oslo, Norway
๐ฆ๐บRoyal Adelaide Hospital, Adelaide, South Australia, Australia
๐ฆ๐บAlfred Hospital, Melbourne, Victoria, Australia
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 195
- Registration Number
- NCT04250155
- Locations
- ๐ง๐ช
GasthuisZusters Antwerpen, Wilrijk, Antwerp, Belgium
๐ฎ๐นIstituto Clinico Humanitas, Rozzano, Lombardia, Italy
๐ฐ๐ทSeverance Hospital Yonsei University Health System - PPDS, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.